C4 Therapeutics (CCCC) EPS (Weighted Average and Diluted) Growth (1y) (2022 - 2026)
C4 Therapeutics (CCCC) EPS (Weighted Average and Diluted) Growth (1y) (2022 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EPS (Weighted Avg. Diluted) Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
251.11% |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
-13.31% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
102.51% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-79.34% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
-103.05% |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
61.45% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
C4 Therapeutics |
520.69 Mn |
285.02 Mn |
- |
45.95% |
| Date | Value |
|---|
| Mar 31, 2026 |
45.95% |
| Dec 31, 2025 |
81.63% |
| Sep 30, 2025 |
-25.71% |
| Jun 30, 2025 |
-42.31% |
| Mar 31, 2025 |
9.76% |
| Dec 31, 2024 |
27.94% |
| Sep 30, 2024 |
36.36% |
| Jun 30, 2024 |
64.38% |
| Mar 31, 2024 |
42.25% |
| Dec 31, 2023 |
10.53% |
| Sep 30, 2023 |
15.38% |
| Jun 30, 2023 |
-30.36% |
| Mar 31, 2023 |
-9.23% |
| Dec 31, 2022 |
-145.16% |
| Sep 30, 2022 |
-27.45% |
| Jun 30, 2022 |
-9.80% |
